Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research, Inc. is a Canadian specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units: the Topical Products and Technology (TPT) Group (formerly the Pain Group) and the Immunology Group.
Price: $5.45 | Change: $-3.55 | %Change: -39.44%
Volume: 456,506 | Day High/Low: 5.65/4.75 | 52 Week High/Low: 10.36/2.40
View modes: 
3 stars

RE:RE:RE:Not that anyone cares on this board

My guess is that this is American selling not buying.  Using a broker who does not trade on the TSX and someone who facilitates the trade charging one cent a share commision.  rate and reply
4 stars

RE:WF10 Phase 2 Results Release Date

took a position today.  now holding GUD  NRI CRH imo they're all part and parcel with GUD GLTA  rate and reply
3 stars

RE:RE:Not that anyone cares on this board

At 3:31 NRIFF had 2 trades of 6000 shares each, exactly one cent different in price. This is not a coincidence. There was a 30 second gap between the two trades. I am now looking for similar size...read more
1 star

RE:Not that anyone cares on this board

I think the after hours trades are being double traded for some kind of bookeeping or something. All the trades are of identical volumes with a one cent difference. EG; the 25,000 was actually two...read more
5 stars

RE:Not that anyone cares on this board

More US investors coming aboard one might presume.  rate and reply
5 stars

Not that anyone cares on this board

but I am finding it oddly interesting how often the after hours trading activity over on the OTC for Nuvo exceeds the trading volume during the day, strange. Not a big buy like the 25K last night or...read more
0 stars

RE:RE:RE:RE:RE:RE:RE:Question

In the WF10 case, the control is placebo. That is because we have a population of non-responders to standard threatment.  rate and reply
5 stars

More Games

Well that 9K trasaction at 11AM sure had its impact.  Whoever is doing this has clearly had success in eliminating the positive views.  Investors are clearly not much interested in buying when the...read more
0.5 stars

RE:RE:RE:RE:RE:RE:RE:Question

Thats correct. If your survey design is correct, the smaller sample results can be extrapolated to larger sample sizes with equal consistency but with smaller variance ( ie higher probability of...read more
5 stars

RE:RE:RE:RE:RE:RE:Question

Directly off the FDA website   Patient Population (1.4.3.2) Selection of subjects for an active control trial can affect outcome; the population studied should be carefully considered in...read more
5 stars

RE:RE:RE:RE:RE:Question

Biotech stock analysts seem to know almost nothing about science and the actual regulatory process. They are obsessed with statistically significant results, but they do not know what it means or what...read more
4.5 stars

RE:RE:RE:RE:Question

Rock I don't wish to get us sidetracked but, to be brief, "significant at the p=0.001 level" generally is taken to mean that, if there actually is no difference between the treatment and control...read more
3 stars

RE:RE:RE:RE:Question

Thanks Rock07, I always appreciate your technical expertise (assuming that it is accurate and unbiased - I know nothing about pharmaceuticals). You say that "... it is almost impossible for P 2...read more
3.5 stars

RE:RE:RE:Question

That study used statistical significance level of p= 0.05. If the survey design were biased , any results would not be acceptable. The 2010 study with 60 subjects was a randomly controlled survey...read more
0 stars

Not sure why anyone

would be selling their shares with a big annoucement coming in February. Someone in USA has been buidling a position during After Hours trading. Another 25K of shares bought on the OTC last night...read more
5 stars

Medical Marijuana Goes To Market: Daniel Pearlstein Of M Par

At the end of this interview.... Daniel talks about Nuvo. http://seekingalpha.com/article/2806795-medical-marijuana-goes-to-market-daniel-pearlstein-of-m-partners TLSR: Are there any other...read more
2.5 stars

RE:RE:Question

Tx Rock , may i go with another one:  regarding GUD and the relation they add in the past with Nuvo, why  didn,t jump in with Pennsaid 2%? A product already approved? Distribution seem the core...read more
2.5 stars

RE:RE:Question

Rock I'm not sure what you meant by "the high statistical significance of initial trials makes the answer obvious". You might find this article by Ioannidis of interest; it addresses research design...read more
0 stars

WF10 Phase 2 Results Release Date

Looking to take a position soon based on fundamentals and market momentum. Can you someone please advise when the WF10 Phase 2 Results will be released?  I recall somewhere saying mid-Feb Thank you...read more
2.5 stars

RE:Question

Only in the case of an open data room. Thats not the case here. However, informal exchanges will be made unless the bid is hostile. Regardless, the high statistical significance of initial trials...read more